Sign in
CTCXW Stock Price, Chart, Stats & News
Carmell Therapeutics Corporation
Save
Carmell Therapeutics Corporation (CTCXW) does not currently pay a dividend.
558,174
Market cap
–
Current P/E
–
Forward P/E
CTCXW chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 54.63% |
Operating margin | -400.96% |
Pretax margin | -400.30% |
Net margin | -393.63% |
Effective tax rate | 1.67% |
ROA | -173.88% |
ROE | 141.35% |
D/E | -0.16x |
Interest coverage ratio | -290.33x |
CTCXW valuation
P/E | – |
P/S | 0.31x |
P/B | -0.13x |
P/CF | -0.14x |
P/FCF | -0.12x |
P/OCF | -0.14x |
PEG | 0.00x |
EV multiple | -0.17x |
About
Carmell Therapeutics Corporation concentrates its efforts on developing sophisticated plasma-derived bioactive materials (PBMs) engineered to promote tissue regeneration and healing. These innovative biomaterials are designed to assist the body's repair mechanisms following trauma, disease, or age-related degeneration. Its flagship experimental product, CT-101, acts as a bone healing accelerator with a wide array of intended uses, including the rapid mending of fractured tibias, facilitating foot and ankle joint fusion, aiding spinal fusion surgeries, serving as an alternative for dental bone grafts, and filling bone voids.
Similar securities
Based on sector and market capitalization
Report issue